These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 8846625)

  • 1. Clinical pharmacokinetics and pharmacodynamics of finasteride.
    Steiner JF
    Clin Pharmacokinet; 1996 Jan; 30(1):16-27. PubMed ID: 8846625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.
    Peters DH; Sorkin EM
    Drugs; 1993 Jul; 46(1):177-208. PubMed ID: 7691505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.
    Ekman P
    Drug Saf; 1998 Mar; 18(3):161-70. PubMed ID: 9530536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finasteride: the first 5 alpha-reductase inhibitor.
    Sudduth SL; Koronkowski MJ
    Pharmacotherapy; 1993; 13(4):309-25; discussion 325-9. PubMed ID: 7689728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5alpha-reductase inhibitors/finasteride.
    Stoner E
    Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
    Stanczyk FZ; Azen CG; Pike MC
    J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of men on finasteride.
    Gormley GJ
    Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
    Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.
    Cote RJ; Skinner EC; Salem CE; Mertes SJ; Stanczyk FZ; Henderson BE; Pike MC; Ross RK
    Br J Cancer; 1998 Aug; 78(3):413-8. PubMed ID: 9703292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finasteride: a 5 alpha-reductase inhibitor.
    Steiner JF
    Clin Pharm; 1993 Jan; 12(1):15-23. PubMed ID: 7679063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
    Stoner E
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia.
    Nacey JN; Meffan PJ; Delahunt B
    Aust N Z J Surg; 1995 Jan; 65(1):35-9. PubMed ID: 7529489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of finasteride on prostate specific antigen: review of available data.
    Guess HA; Gormley GJ; Stoner E; Oesterling JE
    J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H; Chen J; Braf Z
    Harefuah; 1993 Dec; 125(12):453-6, 496. PubMed ID: 7509305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor.
    Prahalada S; Rhodes L; Grossman SJ; Heggan D; Keenan KP; Cukierski MA; Hoe CM; Berman C; van Zwieten MJ
    Prostate; 1998 May; 35(3):157-64. PubMed ID: 9582084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.